Skip to main content
GutCited

Lactobacillus rhamnosus GG 用于 抗生素相关性腹泻(AAD)

A 证据 多项大型临床试验一致显示出显著的益处。

荟萃分析表明LGG可将AAD发生率降低42%至49%。在抗生素开始使用后48小时内开始服用并持续至完成后7天效果最佳。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

结论

荟萃分析表明LGG可将AAD发生率降低42%至49%。在抗生素开始使用后48小时内开始服用并持续至完成后7天效果最佳。

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs 效果: L. rhamnosus GG used by 91.8% None

研究人群: Italian primary care pediatricians

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI 效果: None None

研究人群: Pediatric patients with GI disorders

Controlled Clinical Trial n=24 2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days vs: LPS-only group (no probiotics) Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines) 效果: None p<0.05 to <0.001

研究人群: Male Wistar albino rats with LPS-induced sepsis

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None 效果: None None

研究人群: Pediatric population

Randomized Controlled Trial Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain) vs: Placebo Outcome: Antibiotic-associated diarrhea incidence 效果: None None

研究人群: Adult patients receiving antibiotics

Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745 vs: Placebo or standard care Outcome: AAD prevention and pediatric gastroenteritis 效果: None None

研究人群: AAD and gastroenteritis patients (review)

Key Statistics

20

研究数量

4000

受试者

↑

Positive

A

等级

Referenced Papers

Journal of pediatric … 2016 233 次引用
Digestive diseases (Basel, … 2016 37 次引用
Journal of clinical … 2015 35 次引用
Current opinion in … 2009 82 次引用
Advances in biochemical … 2008 535 次引用
The Journal of … 2007 265 次引用
The American journal … 2001 648 次引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

general:
10-20 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
aadprevention:
10-20 billion CFU/day (start with antibiotic, continue 7 days after)

上限: Generally well-tolerated up to 40 billion CFU/day in clinical trials

研究中使用的剂量

剂量 持续时间 效果 N
None -- Mixed 279
None -- Positive --
10^9 CFU/day for 14 days 2 weeks Positive 24
None -- Mixed --
Probiotics (multi-strain) -- Positive --
S. boulardii CNCM I-745 -- Positive --
None -- Positive --
Twice daily -- Neutral 2650

最佳服用时间: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

已报告的副作用

  • ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
  • ⚠ Rare reports of bacteremia in severely immunocompromised individuals
  • ⚠ Occasional loose stools during adjustment period
  • ⚠ Very rare: systemic infection in critically ill patients with central venous catheters

已知相互作用

  • ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
  • ● Antifungals (no known interaction but may affect gut flora balance)

可耐受最高摄入量: Generally well-tolerated up to 40 billion CFU/day in clinical trials

在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does Lactobacillus rhamnosus GG help with 抗生素相关性腹泻(AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support 抗生素相关性腹泻(AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for 抗生素相关性腹泻(AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and 抗生素相关性腹泻(AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.

其他成分用于 抗生素相关性腹泻(AAD)

Lactobacillus rhamnosus GG 用于其他健康状况

References

  1. [1] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
  2. [2] Necip Gökhan Taş et al.. Medicina (Kaunas). 2025. Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in Rats. doi:10.3390/medicina61040589 PubMed
  3. [3] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
  4. [4] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
  5. [5] Jamal Shah et al.. Cureus. 2024. A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea in Adult Patients. doi:10.7759/cureus.70881 PubMed
  6. [6] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
  7. [7] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  8. [8] Vincent I Lau et al.. Can J Anaesth. 2022. Health economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): a cost-effectiveness analysis. doi:10.1007/s12630-022-02335-9 PubMed
  9. [9] Elie Akanny et al.. Int J Pharm. 2020. Development of enteric polymer-based microspheres by spray-drying for colonic delivery of Lactobacillus rhamnosus GG. doi:10.1016/j.ijpharm.2020.119414 PubMed
  10. [10] Mario Baù et al.. Pediatr Gastroenterol Hepatol Nutr. 2020. Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study. doi:10.5223/pghn.2020.23.1.35 PubMed
  11. [11] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
  12. [12] Valeria Agamennone et al.. BMC Gastroenterol. 2018. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. doi:10.1186/s12876-018-0831-x PubMed
  13. [13] Jiayi Cai et al.. United European Gastroenterol J. 2018. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. doi:10.1177/2050640617736987 PubMed
  14. [14] Ciro Esposito et al.. Probiotics Antimicrob Proteins. 2018. Frequency of Antibiotic-Associated Diarrhea and Related Complications in Pediatric Patients Who Underwent Hypospadias Repair: a Comparative Study Using Probiotics vs … doi:10.1007/s12602-017-9324-4 PubMed
  15. [15] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
  16. [16] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
  17. [17] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
  18. [18] Sylvia Cruchet et al.. Paediatr Drugs. 2015. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. doi:10.1007/s40272-015-0124-6 PubMed
  19. [19] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
  20. [20] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
  21. [21] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
  22. [22] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
  23. [23] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
  24. [24] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
  25. [25] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
  26. [26] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
  27. [27] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
  28. [28] Riku Korhonen et al.. Inflammation. 2002. Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid. doi:10.1023/a:1019720701230 PubMed
  29. [29] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
  30. [30] R Korhonen et al.. Inflammation. 2001. Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. doi:10.1023/a:1010971703271 PubMed
  31. [31] J A Vanderhoof et al.. J Pediatr. 1999. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. doi:10.1016/s0022-3476(99)70053-3 PubMed
  32. [32] T Arvola et al.. Pediatrics. 1999. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. doi:10.1542/peds.104.5.e64 PubMed

FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。